Navigation Links
FSH Society Releases White Paper on Clinical Trial Readiness

The FSH Society today announced that it has published a report on its recent workshop with government regulators, biopharma companies, and academic thought leaders to discuss the current state of clinical trial preparedness for facioscapulohumeral muscular dystrophy (FSHD). The Society is the world’s largest research-focused patient advocacy organization for FSHD, a hereditary muscle-damaging condition that affects an estimated one million men, women, and children worldwide. There is currently no drug to treat or cure FSHD.

In seeking to speed up the development of treatments and a cure for FSHD, the FSH Society convened the workshop to identify gaps in clinical trial readiness that may delay or hamper existing therapeutic programs. The meeting was moderated by Dr. John Porter, former program director for neuromuscular disease at the National Institute of Neurological Disorders and Stroke (NINDS) and addressed five major areas of interest to the pharmaceutical industry. These included tractability of FSHD as an indication suitable for therapeutic development, status of patient registries and natural history studies, pharmacodynamic biomarkers, imaging biomarkers and clinical trial outcome measures.  For each session, the existing status of each area was presented by key opinion leaders and was followed by extensive discussions with all stakeholders, including academics, pharmaceutical companies and patient advocacy groups with regulatory agencies providing critical feedback and guidance on strategies for consideration. 

“With the increasing number of therapeutics in development for FSHD, the timing of this meeting couldn’t have been more appropriate”, said Mark Stone, President and CEO of the FSH Society.  “The aforementioned gaps impact all therapeutic programs and represent pre-competitive hurdles that can hamper clinical trials and potential treatments for our families. Moreover, the identification of these perceive gaps provide an opportunity for the FSH Society, in concert with our industry partners, academic collaborators, sister patient advocacy groups and patient community to mobilize resources to address them for the benefit of the entire community.”

Jamshid Arjomand, PhD, Chief Science Officer of the FSH Society added “the frank and honest discussions by all participants helped highlight common areas of need which we can collectively address to help expedite therapeutic development for our patient community.  The FSH Society has launched a Therapeutic Accelerator program to resolve these issues and will be working with all interested stakeholders in the prioritization and strategic implementation of proposed solutions.”

This Workshop, “Industry Collaborative for Therapy Development in FSHD,” was designed to critically evaluate the current status of clinical trial readiness and identify opportunities and gaps that could be addressed through a collaboration among key stakeholders in the field—academics, industry, regulators, patient advocates, and the FSH Society.  Presentations and discussion sessions focused on the current status of and efforts needed to advance the identification and validation of pharmacodynamic and imaging biomarkers and clinical outcome assessment measures.  This Report summarizes the proceedings and key outcomes of the Workshop. The workshop was organized by John Porter, PhD, and funded by a generous grant from the Geraldi Norton Foundation.

Read the full white paper: Industry Collaborative Workshop for Therapy Development in FSHD.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Society for Immunotherapy of Cancer Recognizes Cancer Immunotherapy Month™
2. The National Children’s Cancer Society Provides Life-Changing Mentor Relationship
3. Cardiology Society Gets to the “Heart” of Hypertrophic Cardiomyopathy
4. Dr. Mark S. Milner to Present on Cryopreserved Amniotic Membrane at 2019 American Society of Cataract and Refractive Surgery (ASCRS)
5. Society for Immunotherapy of Cancer Announces 2019 Recipient of the Richard V. Smalley, MD, Memorial Award and Lectureship
6. Athletic Trainers’ Society of New Jersey Award Winners Recognized at the ATSNJ 33rd Annual Conference and Business Meeting
7. Neil Riordan, PA, PhD Presents at the 5th Annual Perinatal Stem Cell Society Congress in Salt Lake City, UT on Thursday, February 28th
8. Neil Riordan, PA, PhD Presents at the 5th Annual Perinatal Stem Cell Society Congress in Salt Lake City, UT on Thursday, February 28th
9. Announcing Society for Tennis Medicine and Science 2019 Tennis Medicine Conference
10. The Pennsylvania Athletic Trainers’ Society Young Professionals Committee Hosts Southeast Region CEU Event in Conjunction with Temple University and Go4Ellis
11. Mediaplanet Partners with the American Society of Transplantation, National Kidney Fund and more to Advocate for Organ Donation
Post Your Comments:
(Date:6/16/2019)... , ... June 15, 2019 , ... All families go ... poverty, untreated mental health needs and lack of a support network, they may be ... to remove the children from the home and place them with a relative, familiar ...
(Date:6/14/2019)... ... June 14, 2019 , ... United Breast Cancer Foundation ... for Saturday, July 13th. UBCF is thrilled to return to the “City of ... cancer. This second event was added after an overwhelming response to the Tempur-Pedic® ...
(Date:6/13/2019)... ... June 13, 2019 , ... Endometriosis is a painful, inflammatory disease that occurs when ... , Painful periods , Heavy bleeding , Irregular menstruation , ... , Women’s Excellence uses the latest and newest treatment protocols in dealing with the ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... 30 Second Test (BL30SEC) has been accepted by the 2019 National Conference of ... Appendix N requirements. , The Charm BL30SEC test was validated by third ...
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... Hard money ... just 24 hours and the funds can also be provided quickly. If the documentation ... , Private lenders are able to avoid the federal oversight involved with a traditional ...
Breaking Medicine News(10 mins):
(Date:6/19/2019)... LUIS OBISPO, Calif. (PRWEB) , ... June 19, 2019 , ... ... at the same age and this vitality can be a double-edged sword leading seniors ... Luis Obispo assisted living specialists and Certified Senior Advisors at Elder Placement Professionals ...
(Date:6/19/2019)... ... June 19, 2019 , ... INDIGO ... toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein ... vitro toxicology offerings and allows researchers to perform critical toxicology testing previously available ...
(Date:6/18/2019)... ... June 18, 2019 , ... ... at 11500 W Olympic Blvd Suite 350 Los Angeles, CA, 90064, bringing holistic ... methodologies. , MY Education Guru has created individual programs to assist students ...
Breaking Medicine Technology: